Everest Medicines Secures Exclusive Greater China Rights to Novel PCSK9 Inhibitor Lerodalcibep
核心洞察
Everest Medicines (搜索) acquired exclusive Greater China licensing rights to Lerodalcibep, a third-generation PCSK9 inhibitor that demonstrated superior LDL-C reductions of >60% in cardiovascular disease (搜索) patients.
The novel cholesterol-lowering drug offers patient-friendly features including once-monthly subcutaneous injection without refrigeration requirements, differentiating it from existing PCSK9 inhibitors.
Lerodalcibep showed statistical superiority over Inclisiran in head-to-head trials (p=0.0319) and targets China's massive dyslipidemia (搜索) market of 400 million patients with only 14% treatment penetration.
Everest Medicines (搜索) has secured exclusive Greater China development and commercialization rights to Lerodalcibep, a novel third-generation PCSK9 inhibitor that demonstrated superior cholesterol-lowering efficacy in global phase 3 trials. The licensing agreement with Hasten Biopharmaceutical (搜索) positions Everest to enter China's rapidly expanding cardiovascular therapeutics market, which is projected to reach RMB 10 billion by 2030.
Superior Clinical Performance in Large-Scale Trials
Lerodalcibep demonstrated sustained LDL-C reductions of greater than 60% in patients with or at very high or high risk of cardiovascular disease (搜索) across global phase 3 clinical trials involving over 2,500 patients. In patients with heterozygous familial hypercholesterolemia (搜索), who have more severe LDL-C elevations, the drug achieved reductions exceeding 55%.
The drug's clinical superiority was further validated in the head-to-head LIBerate-VI study, where Lerodalcibep demonstrated statistical superiority over Inclisiran (p=0.0319). These efficacy results were confirmed in a recent phase 3 clinical trial conducted specifically in a Chinese population with or at very high risk of cardiovascular disease (搜索), including familial hypercholesterolemia (搜索).
Patient-Friendly Formulation Addresses Treatment Barriers
Developed by U.S.-based LIB Therapeutics (搜索), Lerodalcibep offers several advantages over existing PCSK9 inhibitors. The drug is formulated as a once-monthly, single small-volume subcutaneous injection that does not require refrigeration at home or during travel. These features address key patient convenience and adherence challenges associated with current PCSK9 inhibitor therapies.
The drug is expected to be indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia (搜索), including heterozygous familial hypercholesterolemia (搜索). Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration and the European Medicines Agency.
Substantial Market Opportunity in China
The Chinese PCSK9 inhibitor market represents significant commercial potential, with multiple approved products generating approximately RMB 3 billion in combined sales and demonstrating 95% year-over-year revenue growth in 2024. According to Frost & Sullivan projections, this market is expected to expand to approximately RMB 10 billion by 2030.
Despite an estimated 400 million individuals in China with dyslipidemia (搜索), only approximately 14% receive lipid-lowering treatment, reflecting low penetration rates and substantial unmet medical need. This treatment gap represents a significant opportunity for innovative therapies like Lerodalcibep to expand patient access to effective cholesterol management.
Strategic Licensing Terms and Timeline
Under the licensing agreement, Everest Medicines (搜索) China will make an initial payment of $29 million (approximately RMB 205 million) to Hasten. The deal structure includes potential development and regulatory milestone payments up to $30 million (RMB 212 million) and sales milestones reaching $280 million (RMB 1.977 billion), plus royalties based on aggregate annual net sales.
Everest plans to submit a Biologics License Application in Greater China during the first half of 2026, with potential approval anticipated in 2027. The drug benefits from patent exclusivity in China through 2039, providing substantial market protection for commercial operations.
Complementary Commercial Strategy
The Lerodalcibep licensing agreement is part of a broader strategic partnership with Hasten that includes a separate commercialization services agreement covering six mature pharmaceutical assets across critical care, cardiovascular, and metabolic disease areas. This comprehensive approach is designed to maximize utilization of Everest's existing commercial infrastructure while establishing a strong cardiovascular disease (搜索) vertical.
The combined agreements are expected to strengthen Everest's commercial foundation in China and enhance its presence in the large and growing cardiovascular therapeutics market, with Lerodalcibep's potential 2027 approval contributing to future revenue growth within the company's cardiovascular portfolio.